Cell & Gene Therapies: A Regulatory Update
Related Insights
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Three ways to improve your chances that insurers will pay for a new CGT
Feb 18, 2021
Podcast
CAR-T boxed warnings: What comes next?
Mar 6, 2024
Blog
CAR-T product development: an assessment of FDA’s final guidance for industry
Feb 27, 2024
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
CAR-T boxed warnings: regulatory precedents and opportunities
Feb 9, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Related Insights
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Three ways to improve your chances that insurers will pay for a new CGT
Feb 18, 2021
Podcast
CAR-T boxed warnings: What comes next?
Mar 6, 2024
Blog
CAR-T product development: an assessment of FDA’s final guidance for industry
Feb 27, 2024
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
CAR-T boxed warnings: regulatory precedents and opportunities
Feb 9, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022